A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Summary
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).
Timeline
- Start
- 2023-01-19
- Primary completion
- 2024-11-27
- Completion
- 2024-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liraglutide | Peptide | 3 mg | Subcutaneous |
| Comparator | Naltrexone/Bupropion | Unknown | — | Oral |
| Comparator | Orlistat | Small molecule | — | Oral |
| Comparator | Phentermine/Topiramate | Unknown | — | Oral |
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |